| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6199443 | Ophthalmology | 2016 | 9 Pages |
Abstract
All 3 anti-VEGF groups showed VA improvement from baseline to 2 years with a decreased number of injections in year 2. Visual acuity outcomes were similar for eyes with better baseline VA. Among eyes with worse baseline VA, aflibercept had superior 2-year VA outcomes compared with bevacizumab, but superiority of aflibercept over ranibizumab, noted at 1 year, was no longer identified. Higher APTC event rates with ranibizumab over 2 years warrants continued evaluation in future trials.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
John A. MD, Adam R. MS, Allison R. MS, Lee M. MD, Neil M. MD, Susan B. MD, Alexander J. MD, Frederick L. MD, G. Robert MD, Chirag MD, Michele ScM, Roy W. MD, PhD,